Transthyretin Amyloidosis: An Expert’s View
01 Jun 2023
Dr Jeremy Quah, Cardiology Fellow at National Heart Institute, talks about a rare disease known as transthyretin amyloidosis (ATTR).
Amyloidosis is the extracellular tissue deposition of fibrils. There are two major forms of cardiac amyloidosis, namely light-chain amyloidosis (AL) and ATTR-CM. The clinical manifestations of ATTR-CM can vary greatly but essentially it presents as either new or worsening heart failure or new conduction system disease.
Amyloidosis is the extracellular tissue deposition of fibrils. There are two major forms of cardiac amyloidosis, namely light-chain amyloidosis (AL) and ATTR-CM. The clinical manifestations of ATTR-CM can vary greatly but essentially it presents as either new or worsening heart failure or new conduction system disease.
Related MIMS Drugs
Resources
MY-PFI-478b
MY-PFI-478b